Idarucizumab
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB09264 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 29 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | hemoglobinopathy | KG + DL |
| 2 | rheumatoid arthritis | KG + DL |
| 3 | partial deletion of the short arm of chromosome 16 | KG + DL |
| 4 | beta-thalassemia with other manifestations | KG + DL |
| 5 | pyruvate kinase deficiency of red cells | KG + DL |
| 6 | hemolytic anemia due to glucophosphate isomerase deficiency | KG + DL |
| 7 | pyropoikilocytosis, hereditary | KG + DL |
| 8 | bronchitis | KG + DL |
| 9 | gout | KG + DL |
| 10 | colobomatous microphthalmia-rhizomelic dysplasia syndrome | KG + DL |
| 11 | osteoarthritis | KG + DL |
| 12 | antithrombin deficiency type 2 | KG + DL |
| 13 | osteoarthritis susceptibility | KG + DL |
| 14 | heparin cofactor 2 deficiency | KG + DL |
| 15 | factor 5 excess with spontaneous thrombosis | KG + DL |
| 16 | brachydactyly-syndactyly syndrome | KG + DL |
| 17 | pseudoachondroplasia | KG + DL |
| 18 | thrombophilia | KG + DL |
| 19 | hepatic porphyria | KG + DL |
| 20 | myocardial infarction | KG + DL |
| 21 | brachyolmia | KG + DL |
| 22 | coronary stenosis | KG + DL |
| 23 | early-onset familial noncirrhotic portal hypertension | KG + DL |
| 24 | idiopathic copper-associated cirrhosis | KG + DL |
| 25 | hepatoportal sclerosis | KG + DL |
| 26 | hepatopulmonary syndrome | KG + DL |
| 27 | primitive portal vein thrombosis | KG + DL |
| 28 | acromesomelic dysplasia, Hunter-Thompson type | KG + DL |
| 29 | brachyolmia-amelogenesis imperfecta syndrome | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.